Follow The Filings

TEVA Teva Pharmaceutical Industries Ltd.

Health Care, filed as TEVA PHARMACEUTICAL INDS LTD (SPONSORED ADS), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

  • 8 exits

In 2026 Q3, 8 managers sold out.

Who owns TEVA

Sorted by value, long equity only, as of 2026 Q3.

History
Glenview Capital Management exited 2026 Q3 Last 2026 Q2 3.1% Exit −3.13% 5,081,091 $172M History
Harry Burn, Sound Shore Management exited 2026 Q3 Last 2026 Q2 4.0% Exit −3.97% 3,804,497 $129M History
David Einhorn, DME Capital Management exited 2026 Q3 Last 2026 Q2 2.5% Exit −2.50% 2,886,059 $98M History
Stanley Druckenmiller, Duquesne Family Office exited 2026 Q3 Last 2026 Q2 0.41% Exit −0.41% 624,999 $21M History
David Witzke, Avidity Partners Management exited 2026 Q3 Last 2026 Q2 1.1% Exit −1.09% 200,000 $6.8M History
Ron Baron, BAMCO Inc. (Baron Capital) exited 2026 Q3 Last 2026 Q2 0.01% Exit −0.01% 138,987 $4.7M History
Cathie Wood, ARK Investment Management exited 2026 Q3 Last 2026 Q2 0.02% Exit −0.02% 68,653 $2.3M History
Farallon Capital Management exited 2026 Q3 Last 2026 Q2 0.01% Exit −0.01% 40,000 $1.4M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TEVA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TEVA insider trades
  • None no insider bought on the open market
  • $45.7M sold by 10 insiders outside a trading plan
  • $33.2M sold by 4 insiders under 10b5-1 plans
  1. Richard Daniell EVP, Europe Commercial
    Sale
    $1.9M 45,003 shares at $42.86 45% of stake
    Traded Nov 9–11 Filed Nov 12
  2. Richard D. Francis CEO
    Planned sale
    $10.6M 250,000 shares at $42.24 21% of stake
    Traded Nov 10 Filed Nov 12
  3. Mark Sabag See "Remarks"
    Sale
    $2M 44,710 shares at $44.14 36% of stake
    Traded Nov 12 Filed Nov 12
  4. Amir Weiss Chief Accounting Officer
    Sale
    $744K 17,289 shares at $43.04 83% of stake
    Traded Nov 9 Filed Nov 12
  5. Mark Sabag See "Remarks"
    Sale
    $1.9M 46,000 shares at $41.93 36% of stake
    Traded Nov 5 Filed Nov 6
  6. Dov Bergwerk Interim Cheif Legal Officer
    Sale
    $1.1M 26,260 shares at $41.72 69% of stake
    Traded Nov 4 Filed Nov 6
  7. Brian Savage Interim Chief Legal Officer
    Sale
    $285K 7,342 shares at $38.85 46% of stake
    Traded Sep 18 Filed Sep 22
  8. Roberto Mignone Director
    Sale
    $14.4M 367,600 shares at $39.06 100% of stake
    Traded Sep 18 Filed Sep 22
  9. Amir Weiss Chief Accounting Officer
    Sale
    $355K 9,445 shares at $37.62 42% of stake
    Traded Aug 21 Filed Aug 25
  10. Ronit Satchi-Fainaro Director
    Sale
    $15K 415 shares at $37.25 0.4% of stake
    Traded Aug 21 Filed Aug 25
  11. Evan Lippman EVP, Business Development
    Planned sale
    $680K 18,600 shares at $36.57 42% of stake
    Traded Aug 17 Filed Aug 19
  12. Tal Zvi Zaks Director
    Sale
    $593 17 shares at $34.87 <0.1% of stake
    Traded Aug 5 Filed Aug 10
  13. Matthew Shields EVP, Global Operations
    Sale
    $322K 9,989 shares at $32.19 100% of stake
    Traded Jun 18 Filed Jun 22
  14. Eliyahu Sharon Kalif CFO
    Planned sale
    $3.6M 106,563 shares at $34.10 62% of stake
    Traded Jun 11 Filed Jun 16
  15. Eliyahu Sharon Kalif CFO
    Planned sale
    $5.5M 153,251 shares at $35.61 47% of stake
    Traded May 14 Filed May 18

Also filed in the last 12 months, not counted as buying or selling: 66 option exercises and 29 sales to cover taxes.

Congress

1 member of Congress traded TEVA in the last three years: 1 buy and 0 sales.

All Congress trades
  1. Alan Armstrong R-OK Buy $1K–$15K Mar 30 filed Jul 21

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
8-K 5.02,7.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
8-K 5.02
8-K 1.01,2.03,9.01
8-K 8.01
8-K 7.01,8.01,9.01
424B5
424B5
8-K 3.03,9.01
8-K 8.01,9.01
8-K 2.02,9.01
10-Q

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $15.85B $16.54B $17.26B
Gross profit $7.64B $8.06B $8.94B
Gross margin * 48.2% 48.7% 51.8%
Net income -$0.559B -$1.64B $1.41B
Net margin * -3.5% -9.9% 8.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $12.48B $12.55B $13.95B
Total non-current assets * $30.98B $26.77B $26.8B
Total assets $43.46B $39.33B $40.75B
Total current liabilities $12.25B $12.8B $13.46B
Total non-current liabilities $24.55B $20.81B $19.38B
Total equity $7.51B $5.37B $7.91B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $1.37B $1.25B $1.65B
Cash from investing $968M $792M $737M
Cash from financing -$1.91B -$1.79B -$2.15B
Net change in cash $393M $74M $256M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf